Aurinia settles Teva patent suit; generic launch no earlier than Dec. 7, 2036
Aurinia Pharmaceuticals said it has settled patent infringement litigation with Teva Pharmaceuticals over Teva's application to sell a generic 7.9 mg voclosporin capsule in the United States. Under the settlement, Teva has stipulated that Aurinia's two U.S. patents are enforceable, valid and would be infringed, and Teva may launch no earlier than December 7, 2036, subject to earlier contingencies and FDA approval. The filing gives no financial figures, and Aurinia's other patent actions continue.
Key points
- Teva stipulated that U.S. Patent Nos. 10,286,036 and 11,622,991 are enforceable, valid and would be infringed, and that the patents expire in December 2037.
- Teva may launch its generic voclosporin no earlier than December 7, 2036, unless defined contingencies occur earlier.
- Teva's U.S. launch also depends on FDA approval of its generic product.
- Aurinia's patent infringement actions against five other companies continue in the U.S. District Court for the District of New Jersey.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.